| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PharmaCyte Biotech, Inc.$0.78
+0.01 (+1.07%)
Market Cap
8.70 M
EPS
-1.04
P/E Ratio
-
Value Trade
63.12 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
93.11 K
Total Assets
55.87 M
Total Liabilities
16.47 M
Equity
38.11 M
D/E Ratio
12,345
-13.83 %
Week
8.03 %
1 Month
13.48 %
3 Month
21.26 %
6 Month
-96.06 %
5 Year
-99.64 %
All Time
Cash Data
Cash Position
20.54 M
Monthly Burn
706.00 K
Runway
26 mo
Burn Trend
SEC Filing
Mar 17, 2026
Overview
Volume
78.22 K
52 Week Range
0.63 - 1.51
% held by Insiders
6.21 %
% held by Institutions
9.01 %
Enterprise Value
-10.97 M
Total Shares
10.74 M
Short %
3.97 %
Float Shares
9.48 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PMCB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PharmaCyte Biotech, Inc. (PMCB) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PMCB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PMCB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PMCB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PMCB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PMCB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PMCBPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications TNF new strategic partner LightSolver named a 2
PharmaCyte Biotech, Inc. has announced an increased investment in TNF Pharmaceuticals, contributing an additional $3 million to support TNF's recent licensing agreement with LightSolver. This agreement is aimed at utilizing LightSolver's innovative light-based computing technology to enhance speed and efficiency in compute-sensitive applications, particularly in cryptocurrency mining. PharmaCyte highlights its strong financial position with more than $55 million in assets as it prepares to explore additional growth opportunities. However, the company acknowledges the risks involved with successfully implementing this new technology and strategy.
Read more →PMCBPharmaCyte Biotech, Inc. Announces $7 Million Capital Raise, Led by Existing Investors
PharmaCyte Biotech, Inc. has announced a $7 million capital raise led by existing investors through the sale of newly designated Series C convertible preferred stock. This private placement, expected to close on August 19, 2025, involves the sale of 7,000 shares convertible into a total of 7,000,000 shares of common stock. The capital raise is viewed as a vote of confidence from investors and aims to strengthen the company's financial position. PharmaCyte plans to use the proceeds to enhance shareholder value and explore strategic alternatives.
Read more →PMCBNew investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) has announced a $5 million investment in Femasys, Inc. (Nasdaq: FEMY), marking an expansion of its corporate strategy to leverage its substantial cash reserves to increase shareholder value. This investment in Femasys, a company dedicated to women's health solutions, includes the appointment of PharmaCyte's interim CEO, Josh Silverman, to Femasys' Board of Directors. The decision comes as PharmaCyte seeks to identify and invest in opportunities outside its drug development to capitalize on its cash position. Nevertheless, PharmaCyte faces challenges, including pending regulatory reviews and clinical holds.
Read more →PMCBPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share
PharmaCyte Biotech has announced a cash tender offer for up to 7,750,000 shares at a price of $3.25 per share, which will expire on June 9, 2023. Concurrently, the company completed a $35 million financing through the sale of convertible redeemable preferred stock and warrants from existing investors. This strategy aims to support the company’s ongoing evaluation of its assets associated with treating pancreatic cancer and enhance shareholder value, despite uncertainties regarding the timeline for evaluation. PharmaCyte emphasized the importance of making informed decisions for shareholders in relation to the tender offer.
Read more →PMCBPharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech announced the authorization of a second $10 million share repurchase program to enhance shareholder value. The program, which takes effect immediately and will run for two years, will be funded by the company's available cash. CEO Josh Silverman emphasized the importance of delivering value to shareholders while managing expenses prudently. The company continues to evaluate its current programs and explore additional strategic opportunities. However, there is uncertainty regarding the program's execution and ongoing evaluations by the Business Review Committee.
Read more →PMCBPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box Las V
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value Topics to Include Continued Analysis of FDA's on IND for Cell-in-a-Box Las Vegas, Nev., October 7, 2022 - (Business Wire) - PharmaCyte Biotech, I
Read more →PMCBPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board LAS VEGAS, NV, August 15, 2022 -- (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on dev
Read more →PMCBPharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation 7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders Circumvents Proper Vetting of Direct
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation LAS VEGAS, NV, July 28, 2022, PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li
Read more →PMCBPharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
PharmaCyte Biotech Commences First Phase of Two-Phase LAS VEGAS, NV, July 21, 2022--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-
Read more →PMCBPharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
Reports Positive Interim Results in Malignant Ascites Mouse Model Study LAS VEGAS, NV, July 19, 2022-(BUSINESS WIRE)-PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its
Read more →PMCBPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 LAS VEGAS, NV, July 11, 2022 (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and maligna
Read more →PMCBPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value LAS VEGAS, NV, June 15, 2022, PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developin
Read more →PMCBPharmaCyte Biotech Appoints Dr. Matthias L hr to Board of Directors
Appoints Dr. Matthias L hr to Board of Directors LAS VEGAS, NV, April 5, 2022 (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation techno
Read more →PMCBThis document may include statements by PharmaCyte Biotech that constitute "forward - looking statements." Such statements are often characterized by the terms "may," "believes," expects" or "anticipates" and do not refl
This document may include statements by PharmaCyte Biotech that constitute "forward - looking statements." Such statements are often characterized by the terms "may," "believes," expects" or "anticipates" and do not reflect facts. Forward - looking statements involve risks, uncer
Read more →PMCBPharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules LAGUNA HILLS, CA, August 19, 2021 (BUSINESS WIRE)-PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies
Read more →PMCBPharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering LAGUNA HILLS, CA, August 9, 2021 (BUSINESS WIRE)-PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes
Read more →PMCBBusiness Entity - Filing Acknowledgement 07/09/2021 Work Order Item Number: Filing Number: Filing Type: Filing Date/Time: Filing Page(s): W2021070900177 - 1446335 20211600085 Certificate Pursuant to NRS 78.209 7/9/2021 8
Business Entity - Filing Acknowledgement 07/09/2021 Work Order Item Number: Filing Number: Filing Type: Filing Date/Time: Filing Page(s): W2021070900177 - 1446335 20211600085 Certificate Pursuant to NRS 78.209 7/9/2021 8:00:00 AM 1 Indexed Entity Information: Entity ID: C22368 -
Read more →PMCBBusiness Entity - Filing Acknowledgement 07/02/2021 Work Order Item Number: Filing Number: Filing Type: Filing Date/Time: Filing Page(s): W2021070200638 - 1435606 20211579456 Amendment After Issuance of Stock 7/2/2021 9:
Business Entity - Filing Acknowledgement 07/02/2021 Work Order Item Number: Filing Number: Filing Type: Filing Date/Time: Filing Page(s): W2021070200638 - 1435606 20211579456 Amendment After Issuance of Stock 7/2/2021 9:56:00 AM 4 Indexed Entity Information: Entity ID: C22368 - 1
Read more →PMCBPharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available LAGUNA HILLS, CA, June 18, 2021--(BUSINESS WIRE)-PharmaCyte Biotech, Inc. ("Company") (OTCQB: PMCB), a biotechnology company focused on developing cellular t
Read more →PMCBPHARMACYTE BIOTECH, INC. SUPPLEMENT DATED JUNE 4, 2021 TO DEFINITIVE PROXY STATEMENT DATED MAY 5, 2021 FOR THE 2021 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, JUNE 16, 2021 This supplement, dated
PHARMACYTE BIOTECH, INC. SUPPLEMENT DATED JUNE 4, 2021 TO DEFINITIVE PROXY STATEMENT DATED MAY 5, 2021 FOR THE 2021 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, JUNE 16, 2021 This supplement, dated June 4, 2021 (the "Supplement"), amends and supplements our proxy
Read more →PMCBPHARMACYTE BIOTECH, INC. 23046 Avenida de la Carlota, Suite 600 Laguna Hills, California 92653 (917) 595-2850
PHARMACYTE BIOTECH, INC. 23046 Avenida de la Carlota, Suite 600 Laguna Hills, California 92653 Dear Fellow Stockholder: You are cordially invited to attend the 2021 Annual Meeting of Stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte," the "Company," "we" or "us") to be
Read more →PMCBPharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits
PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits LAGUNA HILLS, CA April 8, 2020 (BUSINESS NEWSWIRE) - PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signat
Read more →PMCBPHARMACYTE BIOTECH, INC. 23046 Avenida de la Carlota, Suite 600 Laguna Hills, California 92653
PHARMACYTE BIOTECH, INC. 23046 Avenida de la Carlota, Suite 600 Laguna Hills, California 92653 To Our Stockholders: You are cordially invited to attend a Special Meeting of the stockholders of PharmaCyte Biotech, Inc., a Nevada corporation ("PharmaCyte"), to be held at the C
Read more →PMCBPharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors
PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors LAGUNA HILLS, CA, October 10, 2017 (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its s
Read more →PMCBPharmaCyte Restructures Agreements with Austrianova to Strengthen Partnership
Restructures Agreements with Austrianova to Strengthen Partnership LAGUNA HILLS, CA, September 6, 2017 (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes us
Read more →PMCBPharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors
PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors LAGUNA HILLS, CA, July 10, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using
Read more →PMCBPharmaCyte Biotech Appoints Thomas Yuen to Board of Directors
Biotech Appoints Thomas Yuen to Board of Directors LAGUNA HILLS, Calif., May 2, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cel
Read more →PMCBNuvilex Announces Name Change to PharmaCyte Biotech Company's Shares Will Trade under New Ticker Symbol
Announces Name Change to PharmaCyte Biotech Company's Shares Will Trade under New Ticker Symbol PHCB SPRING, MD, January 7, 2014 (GLOBE NEWSWIRE) - Nuvilex, Inc. (OTCQB: NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCy
Read more →PMCBNuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments that Combine Cell-in-a-Box and Cannabinoid-Based Medicine
Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments that Combine Cell-in-a-Box and Cannabinoid-Based Medicine SILVER SPRING, MD, December 1, 2014 (GLOBE NEWSWIRE) - Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell therap
Read more →PMCBNUVILEX, INC. AUDIT COMMITTEE CHARTER This Audit Committee Charter (" Charter ") was adopted by the Board of Directors (" Board ") of Nuvilex, Inc. (" Company ") on
AUDIT COMMITTEE CHARTER This Audit Committee Charter ("Charter") was adopted by the Board of Directors ("Board") of Nuvilex, Inc. ("Company") on September 19, 2014. The Audit Committee of the Board ("Audit Committee") is established to oversee the accounting and financial re
Read more →PMCBNuvilex Enters into an At the Market Banking Agreement with Chardan Capital Markets
Nuvilex Enters into an At the Market Banking Agreement with Chardan SILVER SPRING, MD, May 29, 2014 (GLOBE NEWSWIRE) - Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, an
Read more →PMCBNuvilex Contracts with Austrianova for cGMP-Compliant Cell-in-a-Box Encapsulation of Cells for Clinical Trials Manufacturing Agreement Signed by Nuvilex and Austrianova
Nuvilex Contracts with Austrianova for cGMP-Compliant Cell-in-a-Box Encapsulation of Cells for Clinical Trials Manufacturing Agreement Signed by Nuvilex SILVER SPRING, MD, March 20, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company p
Read more →PMCBNuvilex Announces $27 Million Funding Commitment with Institutional Investor to Advance Late Phase Clinical Trials $2 Million Initial Investment Completed
Nuvilex Announces $27 Million Funding Commitment with Institutional Investor to Advance Late Phase Clinical Trials $2 Million Initial Investment Completed SILVER SPRING, MD, February 20, 2014 - Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company providing cell
Read more →PMCBNuvilex's Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes
Nuvilex's Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes SILVER SPRING, MD., November 7, 2013 (Globe Newswire) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for
Read more →PMCBNuvilex Accelerates Development of Treatments for Cancer and Diabetes With New Corporate Management Structure Kenneth L. Waggoner Appointed Chief Executive Officer and President Dr. Robert F. Ryan Appointed Chief Science
Nuvilex Accelerates Development of Treatments for Cancer and Diabetes With New Corporate Management Structure Kenneth L. Waggoner Appointed Chief Executive Officer and President Dr. Robert F. Ryan Appointed Chief Silver Spring, MD, November 25, 2013 - Nuvilex, Inc. (OTCQB:
Read more →Competitive Position
How PMCB ranks across every disease it competes inCompetitive Position is a premium feature
See how PMCB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial